Macrophages can alternate between two states: an inflammatory state for fighting infection and a non-inflammatory state for ...

Ontunisertib could become the first FDA-approved anti-fibrotic suitable for Crohn’s disease patients with symptomatic ...

STENOVA trial achieves primary endpoint in 103 study participants after 12 weeks of treatment -- -- Pharmacokinetic results confirm gut-restricted profile of ontunisertib in FSCD patients -- -- ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

Tyruko ® (natalizumab-sztn), a biosimilar to Tysabri ® (natalizumab), has been made available by Sandoz, according to developer Polpharma Biologics.

By JESSICA N. REX [email protected] This article is part of the “Meet Your Neighbor Monday” series, highlighting the stories of individuals who make Warren County a special place to live. If you ...

UChicago Medicine has opened the first clinic of its kind in Chicago, and one of only a few nationwide, focused on preconception and pregnancy care for patients with Crohn’s disease and ulcerative ...

Fatigue, pale skin, headaches, gastrointestinal issues, increased inflammation, pain, muscle cramps and vision disturbances ...

Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to survive Groundbreaking PS ...